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Abstract
Most patients with chronic hepatitis C virus (HCV) genotype 1 infection who have had a pre-
vious null response (<2-log10 reduction in HCV RNA by treatment week 12) to peginter-
feron/ribavirin (PegIFN/RBV) do not achieve a sustained virological response (SVR) when
re-treated with a first-generation HCV protease inhibitor (PI) administered in combination
with PegIFN/RBV. We studied the incremental benefits associated with adding mericitabine
(nucleoside analog inhibitor of HCV polymerase) to PI plus PegIFN alfa-2a/RBV-based
therapy in two double-blind randomized multicenter phase 2 trials (with boceprevir in
DYNAMO 1, and with telaprevir in DYNAMO 2). The primary endpoint in both trials was
SVR, defined as HCV RNA <25 IU/mL 12 weeks after the end of treatment (SVR12). Over-
all, the addition of mericitabine to PI plus PegIFN alfa-2a/RBV therapy resulted in SVR12
rates of 60–70% in DYNAMO 1 and of 71–96% in DYNAMO 2. SVR12 rates were similar in
patients infected with HCV genotype 1a and 1b in both trials. The placebo control arms in
both studies were stopped because of high rates of virological failure. Numerically lower
relapse rates were associated with longer treatment with mericitabine (24 versus 12
weeks), telaprevir-containing regimens, and regimens that included 48 weeks of PegIFN
alfa-2a/RBV therapy. No mericitabine resistance mutations were identified in any patient in
either trial. The addition of mericitabine did not add to the safety burden associated with
either telaprevir or boceprevir-based regimens. These studies demonstrate increased SVR
PLOSONE | DOI:10.1371/journal.pone.0145409 January 11, 2016 1 / 20
OPEN ACCESS
Citation:Wedemeyer H, Forns X, Hézode C, Lee
SS, Scalori A, Voulgari A, et al. (2016) Mericitabine
and Either Boceprevir or Telaprevir in Combination
with Peginterferon Alfa-2a plus Ribavirin for Patients
with Chronic Hepatitis C Genotype 1 Infection and
Prior Null Response: The Randomized DYNAMO 1
and DYNAMO 2 Studies. PLoS ONE 11(1):
e0145409. doi:10.1371/journal.pone.0145409
Editor: Chien-Wei Su, Taipei Veterans General
Hosptial, TAIWAN
Received: July 1, 2015
Accepted: December 1, 2015
Published: January 11, 2016
Copyright: © 2016 Wedemeyer et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: A summary of the
protocol and results for the studies NV27780
(NCT01482403) and NV27779 (NCT01482390) are
available on http://roche-trials.com. The clinical study
report is available on request via the Roche Data
Sharing website (http://roche-trials.com/
dataSharingPolicyInformation.action). In addition,
electronic individual patient data can be requested;
these requests should include an analysis plan and
rates and reduced relapse rates in difficult-to-treat patients when a nucleoside polymerase
inhibitor with intermediate antiviral potency is added to regimens containing a first-genera-
tion PI.
Trial Registration: ClinicalTrials.gov NCT01482403 and ClinicalTrials.gov NCT01482390
Introduction
Chronic hepatitis C virus (HCV) infection is estimated to affect approximately 180 million peo-
ple worldwide and is a leading cause of hepatocellular carcinoma, cirrhosis, and liver-related
death [1, 2]. The goal of antiviral treatment is attainment of sustained virological response (SVR),
which is associated with long-term eradication of the virus and interruption of liver disease pro-
gression [3, 4]. Compared with treated patients not attaining SVR, patients who achieve SVR
demonstrate significant reductions in both liver-related and overall mortality [5, 6].
The first direct-acting antiviral agents (DAAs) approved for treatment of chronic HCV
infection were the serine protease inhibitors boceprevir (BOC) and telaprevir (TVR), both of
which are only effective against HCV genotype 1 and must be used in combination with pegin-
terferon alfa/ribavirin [7, 8]. Compared with dual peginterferon alfa/ribavirin therapy, these
protease inhibitor-based triple combinations increase SVR rates in treatment-naïve and previ-
ously treated patients and also decrease the required duration of treatment for most previously
untreated patients [9–13]. Compassionate use and expanded access studies in patients with
more advanced liver disease have demonstrated the effectiveness of BOC- and TVR-based tri-
ple therapies, but have also shown high rates of serious adverse events including anaemia, espe-
cially in patients with advanced cirrhosis [14–16].
The SVR rates attained with BOC- and TVR-based triple therapies are lowest (29−38%)
among patients with a prior null response to peginterferon alfa/ribavirin (defined as<2 log10
decline in HCV RNA by week 12) [12, 13]. One approach to increasing SVR rates among prior
null responders to dual peginterferon alfa/ribavirin therapy is to incorporate a second DAA
into a protease-inhibitor-based regimen (quadruple therapy) [17, 18]. Mericitabine (MCB) is
an investigational nucleoside analog inhibitor of the HCV RNA-dependent RNA polymerase
that has a high barrier to resistance, and is effective against HCV that contains mutations that
confer resistance to protease inhibitors [19–21]. MCB has been evaluated in combination with
peginterferon alfa-2a/ribavirin, with or without ritonavir-boosted danoprevir (danoprevir/r, a
second-generation protease inhibitor), and in interferon-free regimens with danoprevir/r and
setrobuvir [18, 22–25]. Of particular note, 24 weeks of treatment with a four-drug regimen
consisting of MCB, danoprevir/r, and peginterferon alfa-2a/ribavirin demonstrated an SVR
rate of 84% in patients with prior null response to peginterferon/ribavirin [18].
This report summarizes the results of two randomized studies that evaluated the efficacy
and safety of MCB and either BOC (DYNAMO 1) or TVR (DYNAMO 2) in combination with
peginterferon alfa-2a/ribavirin and among patients with chronic HCV genotype 1 infection
who had prior null response to treatment with peginterferon alfa/ribavirin.
Methods
Study designs
DYNAMO 1 and DYNAMO 2 (clinicaltrials.gov identifiers: NCT01482403 and NCT01482390,
respectively) were both randomized, double-blind, international, multicenter, parallel-group,
Phase 2 studies designed to evaluate the efficacy and safety of MCB in combination with pegin-
terferon alfa-2a (PEGASYS1, Roche, Basel, Switzerland) and ribavirin (COPEGUS1, Roche,
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Basel, Switzerland) and either BOC (DYNAMO 1) or TVR (DYNAMO 2) in patients with
chronic HCV genotype 1 infection and prior null response to peginterferon alfa/ribavirin. The
first patients were screened for inclusion in DYNAMO 1 and 2 on November 11 and 14, 2011,
respectively, and the last patient visits occurred on January 27 and 28, 2014.
DYNAMO 1 recruited 58 patients (Fig 1) at 20 primary specialist clinics in Canada, France,
Germany, Spain, and the US; DYNAMO 2 recruited 80 patients (Fig 2) at 31 primary specialist
clinics in Canada, France, Germany, Great Britain, Spain, and the US. Study protocols are
available online (please see S2 File. NV27780F protocol and S3 File. NV27779F protocol).
Fig 1. Patient disposition in DYNAMO 1. BOC, boceprevir; MCB, mericitabine; P/R, peginterferon alfa-2a +
ribavirin.
doi:10.1371/journal.pone.0145409.g001
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Both studies were conducted in accordance with the principles of Good Clinical Practice
and the Declaration of Helsinki and all patients gave written informed consent before undergo-
ing any study procedures. Study protocols were approved by independent ethics committees in
each country. Canada: Conjoint Health Research Ethics Board, Calgary, Alberta; University of
Western Ontario (HSREB), London, Ontario. Germany: Ethik-Kommission der Medizinischen
Hochschule Hannover, Hannover. France: CPP Sud- Méditerranée I, Marseille. Spain: CEIC
Hospital Clinic I Provincial, Barcelona; CEIC Hospitals Vall D'Hebron, Barcelona; CEIC Hos-
pital General Universitario de Valencia, Valencia. UK: KHP Clinical Trials Office, London;
Fig 2. Patient disposition in DYNAMO 2.MCB, mericitabine; P/R, peginterferon alfa-2a + ribavirin; TVR, telaprevir.
doi:10.1371/journal.pone.0145409.g002
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Joint Research Office, Academic Health Science Centre, Imperial College, London; St George’s
Research Office, St George’s University of London, London; RM &GOffice, Bournemouth Uni-
versity, Bournemouth.USA: Western International Review Board, Olympia, WA; QUORUM
review IRB, Seattle, WAUCSDHuman Research Protections Program, La Jolla, CA; McGuire
VA Institutional Review Board, Richmond, VA; Kaiser Foundation Research Institute, Oakland,
CA; Baylor Research Institute Institutional Review Board, Dallas, TX; Weill Cornell Med College
IRB, New York, NY; Saint Louis University IRB, St Louis, MO; Human Studies Subcommittee
VA Long Beach, Long Beach, CA; Metrowest Medical Center IRB, Framingham, MA; WIRB,
Puyallup, WA; Henry Ford Health System IRB, Detroit, MI; LSU Health Sciences Center IRB,
New Orleans LA; KC-VAMCHuman Committee, Kansas City, MO.
Patients
Adult patients with chronic HCV genotype 1a or 1b infection, serum HCV RNA level50,000
IU/mL, a liver biopsy result consistent with the diagnosis of chronic hepatitis C and a prior
null response to peginterferon alfa/ribavirin were eligible for inclusion in the studies. Null
response to prior therapy was defined as a<2-log10 reduction in HCV RNA after at least 12
weeks of treatment. Previous HCV treatment must have been discontinued at least 12 weeks
prior to enrollment.
Patients without cirrhosis/transition to cirrhosis must have had a biopsy within the previous
24 months. In contrast, the liver biopsy may have been obtained at any time in the past in
patients with cirrhosis/transition to cirrhosis. The diagnosis could be confirmed by FibroScan
performed within the previous 12 months, on which elasticity scores12.5 kPa were used to
designate cirrhosis/transition to cirrhosis. A repeat liver biopsy was required to determine cir-
rhosis status in patients with elasticity scores9.5 kPa but<12.5 kPa. Patients with cirrhosis/
transition to cirrhosis must have had an abdominal ultrasound, computerized tomography
scan, or magnetic resonance imaging scan to confirm the absence of hepatocellular carcinoma
within the previous 6 months, endoscopy without evidence of gastroesophageal bleeding within
the previous 24 months, and a serum alfa-fetoprotein level<100 ng/mL. Patients were
excluded if they had received prior treatment with any DAA, were coinfected with hepatitis A
or B virus or human immunodeficiency virus, had a medical condition associated with liver
disease other than HCV infection, a history or evidence of decompensated liver disease and/or
serious coexisting chronic medical or psychiatric conditions.
Treatment
Patients in DYNAMO 1 were randomized (2:2:1) into one of three treatment groups (Fig 3A).
Patients in Arm A received 24 weeks of treatment with MCB, BOC, and peginterferon alfa-2a/
ribavirin (total duration: 24 weeks). The same therapy was administered in Arm B and followed
by 24 weeks of BOC plus peginterferon alfa-2a/ribavirin (total duration: 48 weeks). Patients
randomized to Arm C received 4 weeks of MCB placebo, BOC placebo, and peginterferon alfa-
2a/ribavirin, followed by 20 weeks of MCB placebo, BOC, and peginterferon alfa-2a/ribavirin,
followed by 24 weeks of BOC plus peginterferon alfa-2a/ribavirin, for a total treatment dura-
tion of 48 weeks.
Patients in DYNAMO 2 were randomized (2:2:2:1) between four treatment groups (Fig 3B).
Patients in Arm A received 12 weeks of treatment with MCB, TVR, and peginterferon alfa-2a/
ribavirin, followed by 12 weeks of treatment with MCB plus peginterferon alfa-2a/ribavirin
(total duration: 24 weeks). Patients in Arm B received the same treatment as Arm A, followed
by 24 weeks of peginterferon alfa-2a/ribavirin (total duration: 48 weeks). Those randomized to
Arm C received 12 weeks of treatment with MCB, TVR, and peginterferon alfa-2a/ribavirin,
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followed by 12 weeks of treatment with MCB placebo plus peginterferon alfa-2a/ribavirin, and
24 weeks of peginterferon alfa-2a/ribavirin, for a total treatment duration of 48 weeks. Finally,
patients in Arm D received the same treatment as in Arm C, except that MCB placebo replaced
MCB during the first 12 weeks of treatment (total duration: 48 weeks).
MCB was administered at a dose of 1000 mg BID, BOC at 800 mg TID, TVR at 750 mg TID
and peginterferon alfa-2a at 180 μg/week Ribavirin was given at initial doses of 1000 mg/day
(body weight:<75 kg) or 1200 mg/day (body weight:75 kg) and the daily dose was reduced
in a step-wise manner in 200 mg (1 tablet) decrements in the event of adverse events or labora-
tory abnormalities.
Fig 3. Study designs of DYNAMO 1 (a) and DYNAMO 2 (b). BOC, boceprevir 800 mg TID (at recommended intervals of 7–9 hours); MCB, mericitabine
1000 mg BID; P/R, peginterferon alfa-2a 180 μg once/week + ribavirin 1000 mg/day (<75 kg) or 1200 mg/day (75 kg); PBO, placebo; TVR, telaprevir 750
mg TID (at recommended intervals of 7–9 hours). Control Arms C in DYNAMO 1 and D in DYNAMO 2 were closed due to futility while the studies were
ongoing (27 July 2012 in DYNAMO 1 and 10 July 2012 in DYNAMO 2), after which patients in these groups were given the option to receive mericitabine for a
maximum duration of 24 weeks. MCB was added to the regimen for 5 patients in Arm C in DYNAMO 1 and to the regimen for 9 patients in Arm D in DYNAMO
2 at various time points and for various durations.
doi:10.1371/journal.pone.0145409.g003
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Patients were recruited by the investigators. Randomization was centralized and stratified
by HCV genotype (1a or 1b) and interleukin 28B (IL28B) genetic polymorphism (CC, CT, or
TT). The computer-generated randomization list was maintained by the sponsor and was not
accessible to staff at the study centers or study monitors. Randomization assignments were
communicated to study centers by an interactive voice response system.
Study staff, monitors, and patients were blinded to MCB. Double-blinding was achieved by
using matched placebo tablets.
While the studies were ongoing, emerging data from trials of novel DAA-based regimens
prompted the decision to suspend placebo-controlled evaluations of MCB, and the control
arms of DYNAMO 1 (Arm C) and DYNAMO 2 (Arm D) were closed. Patients previously ran-
domized into these arms could receive MCB in addition to the assigned three-drug regimen at
the investigator’s discretion.
Assessments and outcomes
HCV RNA was extracted with the Roche High Pure PCR Product Purification system and
quantified with the Roche COBAS1 TaqMan1 v2.0 assay according to the manufacturer’s rec-
ommendations (lower limit of quantification: 25 IU/mL, limit of detection 20 IU/mL; Roche
Diagnostics, Indianapolis, IN). Resistance monitoring was conducted on samples from all
patients at baseline and on post-baseline samples for patients with breakthrough (defined as
either a sustained1 log10 IU/mL increase in HCV RNA on2 consecutive measurements
while on treatment compared with the nadir [where the nadir was a1 log10 IU/mL decrease
from baseline after 2 weeks of treatment], or a confirmed quantifiable HCV RNA level [25
IU/mL on2 consecutive measurements] after a confirmed unquantifiable HCV RNA level
[<25 IU/mL on2 consecutive measurements]) or relapse (defined as quantifiable HCV RNA
[25 IU/mL on2 consecutive measurements] after all treatment has been stopped in patients
who had responded to treatment). Population sequencing of the coding regions of nonstruc-
tural protein 3/nonstructural protein 4A (NS3/4A) and nonstructural protein 5B (NS5B) was
performed using standard sequencing methods. Safety assessments included monitoring of
adverse events, laboratory parameters and vital signs.
Statistics
Efficacy analyses were conducted according to the intent-to-treat principle among all random-
ized patients who received at least one study drug dose. Safety analyses included all randomized
patients who received at least one study drug dose and who had at least one post-baseline safety
assessment.
The primary efficacy outcome of both studies was SVR12, defined as HCV RNA<25 IU/
mL 12 weeks after the actual end of treatment. SVR rates were summarized using descriptive
statistics, and confidence intervals (CIs) were constructed using the Wilson score method with-
out continuity correction. No formal hypothesis testing was planned. Pre-planned subgroup
analyses were performed according to HCV genotype 1a or 1b infection and presence or
absence of bridging fibrosis or cirrhosis. Relapse rate was calculated as the proportion of
patients with quantifiable HCV RNA during follow-up among those with a confirmed end-of-
treatment virological response and at least one post-treatment HCV RNA assessment. For the
closed control arms of both studies, only baseline characteristics and safety outcomes are
reported due to the wide variability in treatment received.
In DYNAMO 1, a sample size of 30 patients per arm was planned to provide a 90% CI of
±15% around an expected SVR12 rate of 45–55%. In DYNAMO 2, a sample size of 40 patients
per arm was planned to provide a 90% CI of ±13% around the same expected SVR12 rate. The
Mericitabine plus PI-Based Triple Therapy for Chronic HCV
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planned sample sizes were amended to 60 and 120 patients in DYNAMO 1 and 2, respectively,
following closure of the control arms.
Results
Patient disposition
A total of 58 patients were randomized to Arms A (n = 25), B (n = 20), and C (n = 13) of
DYNAMO 1 (Fig 1). Of the 57 patients who began treatment, 21 (84%), 16 (80%) and 6 (46%)
completed treatment in Arms A, B, and C, respectively. Follow-up was completed by 24 patients
(96%) in Arm A, 18 (90%) in Arm B, and 7 (54%) in Arm C. At the investigator’s discretion,
MCB was added to treatment for five of the 12 patients who received treatment in Arm C.
Eighty patients were randomized between Arms A (n = 21), B (n = 24), C (n = 24), and D
(n = 11) of DYNAMO 2 (Fig 2). Of the 79 who commenced treatment, 21 (100%), 17 (71%), 15
(63%) and 9 (82%) patients completed treatment in Arms A, B, C, and D, respectively. Twenty-
four weeks of follow-up were completed by 17 patients (81%) in Arm A, 20 (83%) in Arm B, 23
(96%) in Arm C and 11 (100%) in Arm D. Nine of the 11 patients in Arm D received MCB at
the investigator’s discretion.
Baseline characteristics
Baseline characteristics of patients enrolled in DYNAMO 1 and DYNAMO 2 are presented in
Table 1. Patients were predominantly male and a majority had HCV genotype 1a infection,
host IL28B non-CC genotype and baseline HCV RNA level800,000 IU/mL. The prevalence
of bridging fibrosis or cirrhosis was 53.4% in DYNAMO 1 and 55% in DYNAMO 2. Within
each study, baseline demographic and disease characteristics were balanced between the treat-
ment arms.
Efficacy
In DYNAMO 1, the rate of SVR12 was consistently greater in Arm B than in Arm A across the
overall population and predefined subgroups, with the highest SVR12 rates observed in noncir-
rhotic patients. The primary endpoint of SVR12 was attained by 60.0% (95% CI: 40.7–76.6%)
of patients in Arm A and 70.0% (95% CI: 48.1–85.5%) of patients in Arm B (Fig 4A, Table 2).
Rates of SVR12 appeared similar between patients with HCV genotype 1a or 1b infection in
Arm A (61.5% and 58.3%) and Arm B (66.7% and 75.0%). Higher rates of SVR12 were
observed in noncirrhotic patients than in those with bridging fibrosis/cirrhosis in Arm A
(64.3% and 54.5%) and Arm B (87.5% and 58.3%). SVR12 rates were identical to SVR24 rates
in all subgroups (Table 2). At the end of 12-weeks follow-up, relapse occurred in 8/23 patients
(34.8%) in Arm A and 2/16 patients (12.5%) in Arm B.
In DYNAMO 2, the highest SVR12 rates were achieved in patients who received both the
longest duration of treatment with MCB and the longest overall treatment duration (Arm B).
SVR12 was attained by 81.0% (95% CI: 60.0–92.3%) of patients in Arm A, 95.7% (95% CI:
79.0–99.2%) of patients in Arm B, and 70.8% (95% CI: 50.8–85.1%) of patients in Arm C (Fig
4B, Table 2). Rates of SVR12 in patients with HCV genotype 1a and 1b infection were 78.6%
and 85.7% in Arm A, 93.3% and 100% in Arm B, and 73.3% and 66.7% in Arm C. Among
patients with bridging fibrosis or cirrhosis, SVR12 was achieved by 80.0% of patients in Arm A,
100.0% in Arm B, and 76.9% in Arm C; corresponding SVR12 rates for noncirrhotic patients
were 81.8%, 88.9%, and 63.6%, respectively. Twelve weeks after the end of treatment, 3/19
patients (15.8%) in Arm A had relapse, whereas no relapses were observed in the other arms
(Table 2).
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Fig 4. SVR12 rates by treatment arm in the overall populations and by HCV genotype and presence/absence of bridging fibrosis or cirrhosis in
DYNAMO 1 (a) and DYNAMO 2 (b). BOC, boceprevir; MCB, mericitabine; P/R, peginterferon alfa-2a + ribavirin; TVR, telaprevir.
doi:10.1371/journal.pone.0145409.g004
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Resistance
In DYNAMO 1, 10 patients in Arm A (two of whom experienced breakthrough [both G1a],
and eight of whom experienced relapse [three G1a, five G1b]) and three patients in Arm B
(one of whom experienced breakthrough [G1a] and two of whom experienced relapse [one
G1a and one G1b]) were monitored for viral resistance.
BOC resistance mutations (in NS3) were identified in seven of these patients: T54S in two
patients in Arm A who relapsed (one G1a and one G1b), V55A in one patient in Arm B who
relapsed (G1b), R155K in one patient in Arm B who relapsed (G1a), V36M-T54S in one patient
in Arm B who experienced breakthrough (G1a), T54S/T-V170A in one patient in Arm A who
relapsed (G1b), A156S-M175L in one patient in Arm A who relapsed (G1b). No MCB resis-
tance mutations were detected. Pre-existing BOC resistance mutations (M175L or T54S/V55I)
were identified in baseline samples from two patients (both of whom achieved an SVR). No
pre-existing MCB resistance mutations were detected.
In DYNAMO 2, two patients in Arm A who experienced relapse (one G1a and one G1b), one
patient in Arm B who experienced breakthrough while on P/R (G1a), and six patients in Arm C
who experienced breakthrough while on P/R (four G1a and two G1b) were monitored for viral
resistance. TVR resistance mutations (in NS3) were identified in seven of these patients: R155K
in two patients in Arm C who experienced breakthrough (G1a), V36M in one patient in Arm A
who relapsed (G1b), T54S in one patient in Arm C who experienced breakthrough (G1b), V36A/
V-T54A/T in one patient in Arm C who experienced breakthrough (G1b), V36M-R155K in one
patient in Arm C who experienced breakthrough (G1a), and V36M-R155R/T in one patient in
ArmA who relapsed (G1a). NoMCB resistance mutations were detected. Pre-existing TVR resis-
tance mutations (V36L or T54S) were identified in baseline samples from two patients (both of
whom achieved an SVR). No pre-existing MCBmutations were detected.
Safety
In DYNAMO 1, all patients experienced at least one adverse event, the majority of which were
of mild or moderate intensity. The most common adverse events included anaemia, dysgeusia
and nausea (Table 3). The incidence of these events was generally similar in each arm, with the
exception of dysgeusia, which was not reported for any patient in Arm C. One patient in Arm
A, four in Arm B, and two in Arm C withdrew due to adverse events. Seven serious adverse
events (SAEs) were reported in six patients, of which three were considered related to study
treatment: thrombocytopenia in one patient in Arm B and two incidences of anemia in the
same patient in Arm C. The SAE of thrombocytopenia related to treatment occurred in a
48-year-old woman whose baseline platelet count was 125 x 109/L. Her lowest platelet count
(19 x 109/L) occurred on study day 133. She was hospitalized on four occasions for platelet
transfusions. All treatment with study medications was discontinued on study day 168. The
two incidences of anemia considered to be related to ribavirin occurred in a 71-year-old
woman whose baseline hemoglobin concentration (135 g/dL) and creatinine clearance (85.8
mL/min) were both in the normal range. On study day 43, her hemoglobin concentration was
74 g/L, at which time she was hospitalized and received treatment with oral iron supplements,
folic acid, and two units of packed red blood cells. Treatment with ribavirin was withheld for
three days. The second episode of anemia occurred on study day 73 (hemoglobin concentration
not reported), at which time all treatment with study drugs was discontinued. On study day 77,
she received a second transfusion of two units of packed red blood cells. No deaths were
reported during the study. High rates of grade3 reductions in hemoglobin and neutrophils
were reported for all three arms of the study; grade 3 platelet decreases were also common
(Table 3).
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In DYNAMO 2, the majority of patients experienced at least one AE, these being generally
of mild or moderate intensity. The most common adverse events occurred with similar fre-
quencies in each arm and included fatigue, rash, and anemia (Table 2). Two patients in Arm A,
four in Arm B, four in Arm C, and two in Arm D discontinued study medication due to adverse
events. Both of the safety-related discontinuations in Arm A and one in Arm D were due to
dermatological events. A total of 15 SAEs were reported in 13 patients. SAEs considered related
to study treatment included: abdominal wall abscess, rash, and anemia (in the same patient),
and rash in Arm A; viral gastroenteritis, neutropenia, and anemia in Arm B; and two occur-
rences of anemia in one patient in Arm C. No patients with SAEs considered to be related to
treatment required hospitalization. All study treatment was discontinued in the patient in Arm
B who experienced anemia, although no treatment was given for the SAE and the event was
considered to have resolved by the time of reporting. Treatment with PegIFN alfa-2a/ribavirin
was interrupted in the patient in Arm B who experienced neutropenia, and the dose of ribavirin
was reduced in the patients in Arms A and C who experienced anemia as SAEs. No deaths
occurred during the study. The most common grade3 laboratory abnormalities were reduc-
tions in hemoglobin and neutrophil count, which affected a substantial proportion of patients
in each study arm (Table 2).
Discussion
The DYNAMO 1 and DYNAMO 2 studies were conducted to evaluate whether the addition of
MCB could improve on the generally low SVR rates achieved with BOC- or TVR-based triple
therapy in patients with chronic HCV genotype 1 infection and prior null response to peginter-
feron alfa-2a/ribavirin. In addition to the requirement for prior null response, both studies
recruited a high proportion of patients with bridging fibrosis or cirrhosis, and so included pop-
ulations that have typically been regarded as difficult-to-treat with first-generation protease
inhibitor-based combinations. Although caution must be applied in drawing cross-trial com-
parisons, SVR12 rates observed in the present studies (70% in Arm B of DYNAMO 1 and 96%
in Arm B of DYNAMO 2) are considerably higher than those previously reported for the
approved first- and second-generation protease inhibitor-based triple regimens in patients
with prior null response (31–46%) [17, 18, 26]. These results suggest that SVR12 rates with
BOC- or TVR-based triple regimens can indeed be increased in this patient population by
incorporation of the second DAAMCB, which has been shown to provide a high barrier to the
development of resistance [18–21, 24].
In both DYNAMO 1 and DYNAMO 2, the highest SVR12 rates and lowest incidences of
relapse were attained when 24 weeks of treatment with an MCB-containing, four-drug regimen
was followed by 24 weeks of peginterferon alfa-2a/ribavirin (administered with BOC in
DYNAMO 1). Consistent with in vitro data [27, 28], we hypothesize that depletion of the
immuno-inhibitory NS3/4A serine protease with DAA-based therapy may restore interferon
responsiveness and so explain the higher SVR rates achieved with extended administration of
peginterferon alfa/ribavirin in patients previously nonresponsive to this combination [29]. The
inclusion of MCB seemed to diminish HCV subtype-dependent differences in SVR12 rates
that have typically been observed in clinical trials of first-generation PI-containing triple ther-
apy regimens [10, 11, 30]. Thus, SVR12 rates were similar in G1b and G1a patients enrolled in
both trials. In contrast, SVR12 rates have generally been higher by 5–29% in G1b than G1a
patients in previous trials of protease inhibitor-based triple therapy [10, 11, 26, 30]. As previ-
ously observed with protease inhibitor-based three-drug regimens [9–12, 26], SVR12 rates
were generally higher among noncirrhotic patients compared with patients with bridging fibro-
sis/cirrhosis.
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The higher SVR12 rates in DYNAMO 1 and DYNAMO 2 relative to prior studies of prote-
ase inhibitor-based triple therapy combinations most likely reflect a reduction in the incidence
of protease inhibitor resistance with the incorporation of MCB into therapy. In particular, the
rate of relapse across Arms A–C of DYNAMO 2 12 weeks after end of treatment (3%) appeared
substantially lower than the 26% relapse rate at week 72 reported in the Phase 3 study of TVR
plus peginterferon alfa/ribavirin among prior null responders [12]. Viral breakthrough on
BOC- or TVR-containing three-drug regimens is associated with the selection of protease
inhibitor-resistant virus, which commonly become established as the predominant population
at the time of treatment failure [31–34]. As expected, BOC or TVR resistance mutations were
found by population sequencing in the majority of patients who experienced treatment failure.
In contrast to first-generation protease inhibitors, MCB has a high barrier to resistance [18–
21], as supported by the absence of MCB-resistant variants in the present studies and in previ-
ous trials of MCB in combination with peginterferon alfa-2a/ribavirin [18, 22–24].
The adverse event profiles of the MCB-containing four-drug regimens, including the rates
of serious adverse events and discontinuations due to safety reasons, were similar to reports for
BOC or TVR in combination with peginterferon/ribavirin, suggesting that MCB did not add to
the safety burden [9–13, 30]. This observation is in line with prior studies in which MCB was
well tolerated as a component of triple or quadruple therapy regimens including peginterferon
alfa/ribavirin and/or danoprevir/r [18, 22, 23]. Consistent with the more favorable tolerability
profile of danoprevir/r compared with first-generation protease inhibitors [35], serious adverse
events and withdrawals due to adverse events were more common in the present studies than
reported for MCB in combination with danoprevir/r and peginterferon alfa/ribavirin [18].
The early termination of the control arms limits the strength of the conclusions that can be
drawn from the DYNAMO studies. However, the SVR12 rates associated with the addition of
MCB to BOC- and TVR-based regimens in these studies are remarkably better than the histori-
cally poor outcomes achieved with BOC- and TVR-based triple therapy in null responders,
especially in patients with advanced liver disease [12, 13, 16]. The ability to detect rare variants
was limited because resistance monitoring was based on population sequencing; however, this
limitation is of minimal clinical significance because even population sequencing is capable of
detecting variants associated with on-treatment failure and relapse.
The treatment of chronic HCV infection is currently undergoing rapid change. At the time
the DYNAMO 1 and DYNAMO 2 studies were designed, BOC- and TVR-containing triple
regimens represented the standard of care for HCV genotype 1 infection [36]; however, these
regimens have now been superseded by treatments based on new DAAs [3, 4]. BOC- and
TVR-based therapies are therefore no longer recommended in US clinical practice guidelines
[3]; in contrast, European clinical guidelines recommend these agents in settings where access
to newer agents is limited [4]. Although a very high SVR12 rate (96%) was attained in Arm B
of DYNAMO 2, a full 48 weeks of treatment with peginterferon-containing therapy was
required to achieve this impressive result. Mericitabine has also been studied in combination
with peginterferon alfa/ribavirin in treatment-naïve patients [22, 23]. While a 24-week
response-guided regimen with MCB was well tolerated, did not select resistant variants and
increased SVR compared with peginterferon alfa/ribavirin [22], given the efficacy and safety
profiles of the new interferon-free regimens, the development of MCB in combination with
peginterferon alfa/ribavirin has been discontinued. Nonetheless, ensuring widespread access to
the novel DAA-based regimens is now a major challenge for management of chronic HCV
infection in clinical practice.
Collectively, the results of the DYNAMO 1 and DYNAMO 2 studies suggest that the addi-
tion of 24 weeks of treatment with a nucleoside analog inhibitor with intermediate antiviral
potency to BOC- or TVR-based combinations improves SVR12 rates.
Mericitabine plus PI-Based Triple Therapy for Chronic HCV
PLOSONE | DOI:10.1371/journal.pone.0145409 January 11, 2016 17 / 20
Supporting Information
S1 File. CONSORT checklist.
(DOC)
S2 File. NV27780F protocol.
(PDF)
S3 File. NV27779F protocol.
(PDF)
Acknowledgments
The authors thank Kenneth Sherman for his contributions to the DYNAMO 2 study
(NCT01482390). Input on study design and Boceprevir supplied by Merck. Support for third-
party writing assistance for this manuscript, furnished by Health Interactions, was provided by
F. Hoffmann-La Roche Ltd.
Author Contributions
Conceived and designed the experiments: HW XF AS AV IN JAT. Performed the experiments:
HW CH SL AS AV JAT. Analyzed the data: HW XF CH SL AS AV SLP IN JAT. Contributed
reagents/materials/analysis tools: HW AV JAT. Wrote the paper: HW XF CH SL AS AV SLP
IN JAT.
References
1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribu-
tion of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl):S45–57. doi: 10.1016/j.jhep.2014.
07.027 PMID: 25086286
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infec-
tion: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4):1333–
42. doi: 10.1002/hep.26141 PMID: 23172780
3. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. http://www.
hcvguidelines.org [Accessed May 14, 2015]. Available from: http://www.hcvguidelines.org.
4. EASL recommendations on treatment of hepatitis C 2015 (in press, available at easl.eu). J Hepatol.
2015.
5. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between
sustained virological response and all-cause mortality among patients with chronic hepatitis C and
advanced hepatic fibrosis. JAMA. 2012; 308(24):2584–93. doi: 10.1001/jama.2012.144878 PMID:
23268517
6. van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, et al. Life expectancy in
patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;
312(18):1927–8. doi: 10.1001/jama.2014.12627 PMID: 25387192
7. Merck and Co. Whitehouse Station, NJ, USA. Victrelis Prescribing Information. 2013.
8. Vertex Pharmaceuticals Inc. Cambridge, MA, USA. Incivek prescribing Information. 2013.
9. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for
untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195–206. doi: 10.1056/
NEJMoa1010494 PMID: 21449783
10. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir
for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405–16. doi:
10.1056/NEJMoa1012912 PMID: 21696307
11. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously
treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1207–17. doi: 10.1056/
NEJMoa1009482 PMID: 21449784
12. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV
infection. N Engl J Med. 2011; 364(25):2417–28. doi: 10.1056/NEJMoa1013086 PMID: 21696308
Mericitabine plus PI-Based Triple Therapy for Chronic HCV
PLOSONE | DOI:10.1371/journal.pone.0145409 January 11, 2016 18 / 20
13. Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, et al. Boceprevir for chronic HCV
genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null
response. J Hepatol. 2014; 60(4):748–56. doi: 10.1016/j.jhep.2013.12.013 PMID: 24362076
14. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, et al. Eligibility and
safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.
PLoS One. 2013; 8(2):e55285. doi: 10.1371/journal.pone.0055285 PMID: 23383319
15. Colombo M, Strasser S, Moreno C, Abrao Ferreira P, Urbanek P, Fernandez I, et al. Sustained virologi-
cal response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir
access program. J Hepatol. 2014; 61(5):976–83. doi: 10.1016/j.jhep.2014.06.005 PMID: 24946280
16. Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, et al. Effectiveness of telaprevir or
boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenter-
ology. 2014; 147(1):132–42 e4. doi: 10.1053/j.gastro.2014.03.051 PMID: 24704719
17. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antivi-
ral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366(3):216–24. doi: 10.1056/
NEJMoa1104430 PMID: 22256805
18. Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, et al. Randomized study of danoprevir/
ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginter-
feron/ribavirin. J Hepatol. 2015; 62(2):294–302. doi: 10.1016/j.jhep.2014.09.013 PMID: 25239078
19. Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan JM, et al. RG7128 alone or in combination
with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selec-
tion of resistant variants in HCV-infected patients. J Infect Dis. 2010; 202(10):1510–9. doi: 10.1086/
656774 PMID: 20942646
20. Le Pogam S, Yan JM, Chhabra M, Ilnicka M, Kang H, Kosaka A, et al. Characterization of hepatitis C
virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside poly-
merase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrob Agents Che-
mother. 2012; 56(11):5494–502. doi: 10.1128/AAC.01035-12 PMID: 22869576
21. Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, et al. In vivo emergence of a novel mutant
L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors
mericitabine and sofosbuvir. J Infect Dis. 2014; 209(5):668–75. doi: 10.1093/infdis/jit562 PMID:
24154738
22. Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, et al. JUMP-C: a randomized trial of meri-
citabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4
patients. Hepatology. 2013; 58(2):514–23. doi: 10.1002/hep.26275 PMID: 23359491
23. Wedemeyer H, Jensen D, Herring R Jr., Ferenci P, Ma MM, Zeuzem S, et al. PROPEL: a randomized
trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4
patients. Hepatology. 2013; 58(2):524–37. doi: 10.1002/hep.26274 PMID: 23348636
24. Jensen DM, Brunda M, Elston R, Gane EJ, George J, Glavini K, et al. Interferon-free regimen contain-
ing setrobuvir in combination with ritonavir-boosted danoprevir and ribavirin with or without mericitabine
in HCV genotype 1 treatment-naive patients: interim results from the ANNAPURNA study. Hepatology.
2013; 58 (Suppl):741A.
25. Gane EJ, Pockros PJ, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, et al. Mericitabine and ritona-
vir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-
SVR study. Liver Int. 2015; 35(1):79–89. doi: 10.1111/liv.12588 PMID: 24814388
26. Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, et al. Simeprevir versus telaprevir
with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus geno-
type 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis.
2015; 15(1):27–35. doi: 10.1016/S1473-3099(14)71002-3 PMID: 25482330
27. Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD. Restoration of the activated Rig-I path-
way in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro
at clinically relevant concentrations. Antimicrob Agents Chemother. 2013; 57(9):4417–26. doi: 10.
1128/AAC.00399-13 PMID: 23836176
28. Zhu Z, Mathahs MM, Schmidt WN. Restoration of type I interferon expression by heme and related tet-
rapyrroles through inhibition of NS3/4A protease. J Infect Dis. 2013; 208(10):1653–63. doi: 10.1093/
infdis/jit338 PMID: 23901085
29. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F, et al. Nonstructural protein 3-4A:
the Swiss army knife of hepatitis C virus. J Viral Hepat. 2011; 18(5):305–15. doi: 10.1111/j.1365-2893.
2011.01451.x PMID: 21470343
30. Sherman KE, FlammSL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided
telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365(11):1014–24.
doi: 10.1056/NEJMoa1014463 PMID: 21916639
Mericitabine plus PI-Based Triple Therapy for Chronic HCV
PLOSONE | DOI:10.1371/journal.pone.0145409 January 11, 2016 19 / 20
31. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, et al. Characterization of resistance
to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009; 50
(6):1709–18. doi: 10.1002/hep.23192 PMID: 19787809
32. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, et al. Evolution of treatment-
emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013; 57(2):221–9. doi:
10.1093/cid/cit226 PMID: 23575197
33. Haseltine EL, De Meyer S, Dierynck I, Bartels DJ, Ghys A, Davis A, et al. Modeling viral evolutionary
dynamics after telaprevir-based treatment. PLoS Comput Biol. 2014; 10(8):e1003772. doi: 10.1371/
journal.pcbi.1003772 PMID: 25101970
34. Ho CK, Welkers MR, Thomas XV, Sullivan JC, Kieffer TL, Reesink HW, et al. A comparison of 454
sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variants. J Virol
Methods. 2015; 219:28–37. doi: 10.1016/j.jviromet.2015.03.018 PMID: 25818622
35. Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, et al. Efficacy and
safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior
null responders. Antimicrob Agents Chemother. 2014; 58(2):1136–45. doi: 10.1128/AAC.01515-13
PMID: 24295986
36. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D.
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the
American Association for the Study of Liver Diseases. Hepatology. 2011; 54(4):1433–44. doi: 10.1002/
hep.24641 PMID: 21898493
Mericitabine plus PI-Based Triple Therapy for Chronic HCV
PLOSONE | DOI:10.1371/journal.pone.0145409 January 11, 2016 20 / 20
